

FISCAL YEAR 2010



NATIONAL INSTITUTES OF HEALTH

TRANS-NIH PLAN FOR HIV-RELATED RESEARCH

Office of AIDS Research

National Institutes of Health

U.S. Department of Health and Human Services



NATIONAL INSTITUTES OF HEALTH

TRANS-NIH PLAN FOR HIV-RELATED RESEARCH

Office of AIDS Research

National Institutes of Health

U.S. Department of Health and Human Services

Contents

Foreword	i
Legislative Mandate	iii
OVERVIEW	1
CHAPTER 1: Foundational Research	
Natural History and Epidemiology	17
Etiology and Pathogenesis	29
CHAPTER 2: Prevention Research	
Microbicides	45
Vaccines	57
Behavioral and Social Science	75
CHAPTER 3: Therapeutics Research	
Therapeutics	89
CHAPTER 4: Research Support and Dissemination	
Training, Infrastructure, and Capacity Building	113
Information Dissemination	121
CHAPTER 5: Research Related to Specific Populations	
Women and Girls	125
Racial and Ethnic Populations	139
Research in International Settings	145
PLANNING GROUPS	167
APPENDICES	
NIH Institutes and Centers	201
List of Acronyms	203

Foreword

It is with pleasure that I present the *Fiscal Year 2010 Trans-NIH Plan for HIV-Related Research*, which will provide the framework for formulation of the fiscal year 2010 budget. The Plan was developed through the annual Office of AIDS Research strategic planning process, which culminates in the identification of the top strategic priorities and critical needs for HIV-related research. I thank everyone who participated in this process to ensure that this Plan is aligned with the state of the science and public health need. Their names are listed in the Planning Groups section of this Plan.

Each year, the Plan reflects the changing science of this dynamic epidemic. This past year, research results had a significant impact on the future direction of AIDS vaccine research. In September 2007, two large Phase IIb studies of HIV vaccine candidates conducted by the NIH in partnership with Merck & Co., Inc., were halted upon recommendation by the Data and Safety Monitoring Board after interim analyses of data revealed the vaccine candidate did not prevent HIV infection. Although the trial results were not what we had hoped they would be, we are learning a number of things about the immune response to the vaccine and other factors that may affect susceptibility to infection. To reflect that change, the Objectives and Strategies under the HIV Vaccine Area of Emphasis in this Plan have been adjusted, and greater emphasis has been placed on the conduct of discovery research that may inform the development of new and innovative vaccine concepts, as well as the development of improved animal models to conduct preclinical evaluations of vaccine candidates.

The *Fiscal Year 2010 Trans-NIH Plan for HIV-Related Research* is a roadmap for NIH AIDS research. In this time of fiscal constraint, only through careful research planning can the NIH continue to support the highest priority HIV-related research and maintain a balanced research portfolio. This Plan will help to ensure that research dollars are invested in the highest priority research that may lead to the development of new tools to combat the global AIDS pandemic.



Jack Whitescarver, Ph.D.

NIH Associate Director for AIDS Research and Director, Office of AIDS Research
October 2008

Legislative Mandate

Section 2353(c)(1) of the Public Health Service Act provides that the Director of the Office of AIDS Research (OAR) “shall plan, coordinate and evaluate research and other activities conducted or supported” by the NIH. The Director of OAR “shall act as the primary Federal official with responsibility for overseeing all AIDS research conducted or supported by the National Institutes of Health” and “shall establish a comprehensive plan for the conduct and support of all AIDS activities of the agencies of the National Institutes of Health...; ensure that the Plan establishes priorities among the AIDS activities that such agencies are authorized to carry out; ensure that the Plan establishes objectives regarding such activities...; and ensure that the Plan serves as a broad, binding statement of policies regarding AIDS activities of the agencies, but does not remove the responsibility of the heads of the agencies for the approval of specific programs or projects, or for other details of the daily administration of such activities, in accordance with the Plan.” The law further provides that “the Director of the OAR shall ensure that the Plan provides for basic research; provides for applied research; provides for research that is supported and conducted by the agencies; provides for proposals developed pursuant to solicitations by the agencies and for proposals developed independently of such solicitations; and provides for behavioral research and social science research.”

